Literature DB >> 18001769

Structural basis for catalysis by onconase.

J Eugene Lee1, Euiyoung Bae, Craig A Bingman, George N Phillips, Ronald T Raines.   

Abstract

Onconase (ONC) is a homolog of bovine pancreatic ribonuclease (RNase A) from the frog Rana pipiens. ONC displays antitumoral activity and is in advanced clinical trials for the treatment of cancer. Here, we report the first atomic structures of ONC-nucleic acid complexes: a T89N/E91A ONC-5'-AMP complex at 1.65 A resolution and a wild-type ONC-d(AUGA) complex at 1.90 A resolution. The latter structure and site-directed mutagenesis were used to reveal the atomic basis for substrate recognition and turnover by ONC. The residues in ONC that are proximal to the scissile phosphodiester bond (His10, Lys31, and His97) and uracil nucleobase (Thr35, Asp67, and Phe98) are conserved from RNase A and serve to generate a similar bell-shaped pH versus k(cat)/K(M) profile for RNA cleavage. Glu91 of ONC forms two hydrogen bonds with the guanine nucleobase in d(AUGA), and Thr89 is in close proximity to that nucleobase. Installing a neutral or cationic residue at position 91 or an asparagine residue at position 89 virtually eliminated the 10(2)-fold guanine:adenine preference of ONC. A variant that combined such substitutions, T89N/E91A ONC, actually preferred adenine over guanine. In contrast, installing an arginine residue at position 91 increased the guanine preference and afforded an ONC variant with the highest known k(cat)/K(M) value. These data indicate that ONC discriminates between guanine and adenine by using Coulombic interactions and a network of hydrogen bonds. The structure of the ONC-d(AUGA) complex was also used to probe other aspects of catalysis. For example, the T5R substitution, designed to create a favorable Coulombic interaction between ONC and a phosphoryl group in RNA, increased ribonucleolytic activity by twofold. No variant, however, was more toxic to human cancer cells than wild-type ONC. Together, these findings provide a cynosure for understanding catalysis of RNA cleavage in a system of high medicinal relevance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18001769      PMCID: PMC2151974          DOI: 10.1016/j.jmb.2007.09.089

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  76 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Ribonuclease A.

Authors:  Ronald T. Raines
Journal:  Chem Rev       Date:  1998-05-07       Impact factor: 60.622

3.  On the molecular discrimination between adenine and guanine by proteins.

Authors:  I Nobeli; R A Laskowski; W S Valdar; J M Thornton
Journal:  Nucleic Acids Res       Date:  2001-11-01       Impact factor: 16.971

Review 4.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

5.  Contribution of chain termini to the conformational stability and biological activity of onconase.

Authors:  E Notomista; F Catanzano; G Graziano; S Di Gaetano; G Barone; A Di Donato
Journal:  Biochemistry       Date:  2001-08-07       Impact factor: 3.162

6.  Mechanism of RNase T1: concerted triester-like phosphoryl transfer via a catalytic three-centered hydrogen bond.

Authors:  S Loverix; A Winqvist; R Strömberg; J Steyaert
Journal:  Chem Biol       Date:  2000-08

7.  Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

Authors:  Stanislaw M Mikulski; John J Costanzi; Nicholas J Vogelzang; Spence McCachren; Robert N Taub; Hoo Chun; Abraham Mittelman; Timothy Panella; Carmelo Puccio; Robert Fine; Kuslima Shogen
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity.

Authors:  Y Wu; S M Mikulski; W Ardelt; S M Rybak; R J Youle
Journal:  J Biol Chem       Date:  1993-05-15       Impact factor: 5.157

9.  Binding of placental ribonuclease inhibitor to the active site of angiogenin.

Authors:  F S Lee; B L Vallee
Journal:  Biochemistry       Date:  1989-04-18       Impact factor: 3.162

10.  Crystal structure of ribonuclease A.d(ApTpApApG) complex. Direct evidence for extended substrate recognition.

Authors:  J C Fontecilla-Camps; R de Llorens; M H le Du; C M Cuchillo
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

View more
  14 in total

Review 1.  Protein crystallography for non-crystallographers, or how to get the best (but not more) from published macromolecular structures.

Authors:  Alexander Wlodawer; Wladek Minor; Zbigniew Dauter; Mariusz Jaskolski
Journal:  FEBS J       Date:  2007-11-23       Impact factor: 5.542

Review 2.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 3.  Ribonucleases as novel chemotherapeutics : the ranpirnase example.

Authors:  J Eugene Lee; Ronald T Raines
Journal:  BioDrugs       Date:  2008       Impact factor: 5.807

Review 4.  Ribonucleases as potential modalities in anticancer therapy.

Authors:  Wojciech Ardelt; Barbara Ardelt; Zbigniew Darzynkiewicz
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

5.  Interaction of onconase with the human ribonuclease inhibitor protein.

Authors:  Rebecca F Turcotte; Ronald T Raines
Journal:  Biochem Biophys Res Commun       Date:  2008-10-16       Impact factor: 3.575

6.  Onconase cytotoxicity relies on the distribution of its positive charge.

Authors:  Rebecca F Turcotte; Luke D Lavis; Ronald T Raines
Journal:  FEBS J       Date:  2009-06-11       Impact factor: 5.542

7.  Crystal structure of Onconase at 1.1 Å resolution--insights into substrate binding and collective motion.

Authors:  Daniel E Holloway; Umesh P Singh; Kuslima Shogen; K Ravi Acharya
Journal:  FEBS J       Date:  2011-09-28       Impact factor: 5.542

8.  Structure and activity of the only human RNase T2.

Authors:  Andrea Thorn; Robert Steinfeld; Marc Ziegenbein; Marcel Grapp; He-Hsuan Hsiao; Henning Urlaub; George M Sheldrick; Jutta Gärtner; Ralph Krätzner
Journal:  Nucleic Acids Res       Date:  2012-06-26       Impact factor: 16.971

9.  Towards tricking a pathogen's protease into fighting infection: the 3D structure of a stable circularly permuted onconase variant cleavedby HIV-1 protease.

Authors:  Mariona Callís; Soraya Serrano; Antoni Benito; Douglas V Laurents; Maria Vilanova; Marta Bruix; Marc Ribó
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

10.  Ribonuclease A homologues of the zebrafish: polymorphism, crystal structures of two representatives and their evolutionary implications.

Authors:  Konstantina Kazakou; Daniel E Holloway; Stephen H Prior; Vasanta Subramanian; K Ravi Acharya
Journal:  J Mol Biol       Date:  2008-05-04       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.